{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:06:14Z","timestamp":1790222774635,"version":"4.1.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Breast cancer treatment is associated with cancer-related cognitive impairment (CRCI). However, the association of endocrine therapy (ET) vs chemotherapy plus endocrine therapy (CET) with CRCI is poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare patient-reported CRCI between women with breast cancer treated with ET vs CET and to consider whether menopausal status may be associated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Settings, and Participants<\/jats:title>\n                    <jats:p>\n                      This was a prespecified secondary analysis of RxPONDER (SWOG S1007), a multinational phase 3 randomized clinical trial of more than 5000 women with hormone receptor\u2212positive\n                      <jats:italic>ERBB2<\/jats:italic>\n                      -negative (formerly\n                      <jats:italic>HER2<\/jats:italic>\n                      -negative) breast cancer with 1 to 3 involved lymph nodes and Oncotype DX (21-gene recurrence score) of 25 or less. Participants were enrolled from February 2011 to September 2017, with results first reported in December 2020. Participants were randomly assigned to CET or ET, with ongoing follow-up. This secondary analysis assessed cognitive function using the Patient-Reported Outcomes Measurement Information System Perceived Cognitive Function Concerns (PCF) questionnaire at baseline, 6, 12, and 36 months. Data were analyzed from July 2022 to August 2025.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Random assignment to CET or ET.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Mean PCF standardized (T) scores by menopausal status over time using generalized estimating equations analysis for continuous outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 568 patients who completed the baseline questionnaire and were included in the analysis, 139 (24%) were premenopausal (median [range] age, 47.8 [28.0-56.3] years) and 429 (76%) were postmenopausal (median [range] age, 62.3 [37.3-87.6] years). Among the 274 (48%) who received CET and the 294 (52%) who received ET alone, CET was determined to have a greater negative association with patient-reported CRCI in both the pre- and postmenopausal participants during the 36-month follow-up. In the ET alone group, PCF scores for premenopausal participants decreased from baseline to 6 and 12 months (53.53, 51.51, and 51.72, respectively) but recovered to baseline (54.36) at 36 months. For postmenopausal participants, mean PCF scores were essentially stable (51.72, 51.13, 51.11, and 51.70, respectively); however, in the CET group, PCF scores for both pre- and postmenopausal participants decreased from baseline to 6 and 12 months (premenopausal, 52.84, 49.27, 48.04; postmenopausal, 50.65, 48.39, 47.13, respectively) and did not return to baseline at 36 months (premenopausal, 49.25; postmenopausal, 48.44). The difference in longitudinal mean PCF scores over time between CET and ET groups was \u22123.02 (95% CI, \u22125.33 to \u22120.72;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.01) for premenopausal and \u22122.37 (95% CI, \u22123.92 to \u22120.82;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.003) for postmenopausal participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This secondary analysis of the RxPONDER found that CET had a greater negative association with patient-reported CRCI compared to ET alone in both pre- and postmenopausal participants over a 36-month follow-up period. Interventions to prevent or treat CRCI are needed to improve the long-term quality of life of these patients treated with chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/study\/\">NCT01272037<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.5220","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:00:27Z","timestamp":1765468827000},"page":"159","source":"Crossref","is-referenced-by-count":7,"title":["Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women"],"prefix":"10.1001","volume":"12","author":[{"given":"Irene M.","family":"Kang","sequence":"first","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie K.","family":"Forschmiedt","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Loch","sequence":"additional","affiliation":[{"name":"Louisiana State University, New Orleans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danika L.","family":"Lew","sequence":"additional","affiliation":[{"name":"Southwest Oncology Group Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Barlow","sequence":"additional","affiliation":[{"name":"Southwest Oncology Group Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Gralow","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy S.","family":"Albain","sequence":"additional","affiliation":[{"name":"Loyola University Chicago Stritch School of Medicine, Maywood, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Hayes","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith A.","family":"Perez","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Rastogi","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne F.","family":"Schott","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Baehner","sequence":"additional","affiliation":[{"name":"Exact Sciences, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Tripathy","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9472","key":"coi250075r1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","journal-title":"Lancet"},{"issue":"10001","key":"coi250075r2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","journal-title":"Lancet"},{"issue":"10384","key":"coi250075r3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"coi250075r4","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"34","author":"Harris","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250075r5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"coi250075r6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO Guideline Update.","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"coi250075r7","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"30","key":"coi250075r8","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1200\/JCO.2012.43.0116","article-title":"Cancer- and cancer treatment-associated cognitive change: an update on the state of the science.","volume":"30","author":"Ahles","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250075r9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1200\/JCO.2016.68.5826","article-title":"Cognitive Complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study.","volume":"35","author":"Janelsins","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi250075r10","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00520-020-05860-9","article-title":"Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.","volume":"29","author":"Mayo","year":"2021","journal-title":"Support Care Cancer"},{"issue":"12","key":"coi250075r11","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/jnci\/djab027","article-title":"Measuring self-reported cancer-related cognitive impairment: recommendations from the Cancer Neuroscience Initiative Working Group.","volume":"113","author":"Henneghan","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"coi250075r12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10549-023-06968-2","article-title":"Validating the PROMIS cognitive function short form in cancer survivors.","volume":"201","author":"Henneghan","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"coi250075r13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2016.71.4410","article-title":"United States population-based estimates of patient-reported outcomes measurement information system symptom and functional status reference values for individuals with cancer.","volume":"35","author":"Jensen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"coi250075r14","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.19.01866","article-title":"Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx.","volume":"38","author":"Wagner","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi250075r15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11764-018-0692-x","article-title":"Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.","volume":"12","author":"Bray","year":"2018","journal-title":"J Cancer Surviv"},{"issue":"3","key":"coi250075r16","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00520-020-05616-5","article-title":"Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems.","volume":"29","author":"Gutenkunst","year":"2021","journal-title":"Support Care Cancer"},{"issue":"2","key":"coi250075r17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10549-014-3092-6","article-title":"Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation.","volume":"147","author":"Askren","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"coi250075r18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1037\/a0033425","article-title":"Pretreatment worry and neurocognitive responses in women with breast cancer.","volume":"33","author":"Berman","year":"2014","journal-title":"Health Psychol"},{"issue":"1","key":"coi250075r19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11682-016-9507-8","article-title":"Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis.","volume":"11","author":"Jung","year":"2017","journal-title":"Brain Imaging Behav"},{"issue":"12","key":"coi250075r20","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/cancers11121896","article-title":"Long-term fatigue and cognitive disorders in breast cancer survivors.","volume":"11","author":"Joly","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"17","key":"coi250075r21","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1007\/s11764-022-01220-0","article-title":"Long-term changes of cognitive impairment among older breast cancer survivors.","author":"Luo","year":"2023","journal-title":"J Cancer Surviv"},{"issue":"2","key":"coi250075r22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae268","article-title":"Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study.","volume":"30","author":"Kerkmann","year":"2025","journal-title":"Oncologist"},{"issue":"16","key":"coi250075r23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS612","article-title":"A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+\/HER2- breast cancer (BC) and oncotype recurrence score (RS) =25 (OFSET): NRG-BR009.","volume":"42","author":"Swain","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi250075r25","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s10072-019-03898-0","article-title":"Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options.","volume":"40","author":"Di Iulio","year":"2019","journal-title":"Neurol Sci"},{"issue":"3","key":"coi250075r26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4103\/apjon.apjon_16_18","article-title":"Cancer-related cognitive impairment in breast cancer patients: influences of psychological variables.","volume":"5","author":"Yang","year":"2018","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"11","key":"coi250075r27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/jnci\/djt073","article-title":"Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance.","volume":"105","author":"Ganz","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"coi250075r24","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Survivorship","author":"Sanft","year":"2023"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2842808\/jamaoncology_kang_2025_oi_250075_1771446071.87493.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:01:00Z","timestamp":1771516860000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2842808"}},"subtitle":["A Secondary Analysis of the RxPONDER Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.5220","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}